QC
JANX icon

Quadrature Capital’s Janux Therapeutics JANX Stock Holding History

Quadrature Capital’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-22,889
Closed -$318K – 1829
2026
Q1 		$318K Sell
22,889
-10,113
-31% -$139K ﹤0.01% 955
2025
Q4 		$455K Buy
33,002
+6,141
+23% +$144K ﹤0.01% 721
2025
Q3 		$656K Buy
+26,861
New +$654K 0.01% 453

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Quadrature Capital's JANX Position: Q2 2026 in Review

Quadrature Capital sold out of Janux Therapeutics (JANX) in Q2 2026, closing a stake of 22,889 shares — an estimated $318K sold.

Quadrature Capital first reported a position in JANX in Q3 2025 and held it in 3 quarters. The position peaked at $656K in Q3 2025. 197 funds tracked by Wall St. Rank hold JANX as of Q2 2026.

  • Quadrature Capital reported no remaining Janux Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Quadrature Capital sold 22,889 Janux Therapeutics shares in Q2 2026, an estimated $318K.
  • Quadrature Capital first reported a position in Janux Therapeutics in Q3 2025 and held it in 3 quarters.
  • Quadrature Capital's Janux Therapeutics position peaked at $656K in Q3 2025.
  • 197 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2026.

Based on Quadrature Capital's 13F filing for Q2 2026, filed 7 Aug 2026.